Targeted Nanotechnology in Glioblastoma Multiforme

Autor(es)

Glaser, Talita ; Han, Inbo ; Wu, Liquan ; Zeng, Xiang

• Tipo de documento: Artigo de Revisão
• Fonte: FRONTIERS IN PHARMACOLOGY; v. 8, MAR 31 2017.
• Citações Web of Science: 27

Resumo

Gliomas, and in particular glioblastoma multiforme, are aggressive brain tumors characterized by a poor prognosis and high rates of recurrence. Current treatment strategies are based on open surgery, chemotherapy (temozolomide) and radiotherapy. However, none of these treatments, alone or in combination, are considered effective in managing this devastating disease, resulting in a median survival time of less than 15 months. The efficiency of chemotherapy is mainly compromised by the blood-brain barrier (BBB) that selectively inhibits drugs from infiltrating into the tumor mass. Cancer stem cells (CSCs), with their unique biology and their resistance to both radio-and chemotherapy, compound tumor aggressiveness and increase the chances of treatment failure. Therefore, more effective targeted therapeutic regimens are urgently required. In this article, some well-recognized biological features and biomarkers of this specific subgroup of tumor cells are profiled and new strategies and technologies in nanomedicine that explicitly target CSCs, after circumventing the BBB, are detailed. Major achievements in the development of nanotherapies, such as organic poly(propylene glycol) and poly(ethylene glycol) or inorganic (iron and gold) nanoparticles that can be conjugated to metal ions, liposomes, dendrimers and polymeric micelles, form the main scope of this summary. Moreover, novel biological strategies focused on manipulating gene expression (small interfering RNA and clustered regularly interspaced short palindromic repeats {[}CRISPR]/CRISPR associated protein 9 {[}Cas 9] technologies) for cancer therapy are also analyzed. The aim of this review is to analyze the gap between CSC biology and the development of targeted therapies. A better understanding of CSC properties could result in the development of precise nanotherapies to fulfill unmet clinical needs. (AU)

• Processo FAPESP: 15/13345-1 - Doença de Huntington: envolvimento de Huntingtin no controle do comprometimento celular
• Beneficiário: Talita Glaser
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 16/07659-6 - Envolvimento da proteína Huntingtin na escolha do destino celular de neurônios GABAérgicos derivados de iPSCs de portadores da Doença de Huntington.
• Beneficiário: Talita Glaser
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Pós-Doutorado